钦州湾秋季和春季浮游动物分布特征及影响因素

为了解钦州湾浮游动物群落的时空分布特征及与主要环境因子的关系,于2014年10月和2015年3月进行了秋季和春季两航次的调查。结果表明:该海湾的浮游动物群落有明显的季节变化。秋季共鉴定出12类87种,其中优势种有太平洋纺锤水蚤(Acartia pacifica)、肥胖三角溞(Evadne tergestina)、亨生莹虾(Lucifer hanseni)、百陶箭虫(Sagitta bedoti)和长尾类幼虫(Macrura larvae);春季共鉴定出11类48种,优势种为中华哲水蚤(Calanus sinicus)和太平洋纺锤水蚤;秋季浮游动物的平均丰度、生物量和多样性指数(528.92个/m~3、110.60 mg/m~3和2.22)均高于春季(48.30个/m~3、61.10 mg/m~3和1.70)。空间分布上,钦州湾外湾浮游动物丰度、生物量和多样性指数的平均值皆高于内湾。多维尺度分析表明,秋季内湾群落相似性较高,春季外湾浮游动物群落相似性较高。相关性分析表明盐度与营养盐是影响钦州湾浮游动物分布的主要环境因子。与2011—2012年数据相比,钦州湾浮游动物群落结构已趋于单一化和小型化,以致生物量明显下降。这一现象主要与钦州湾海水富营养化以及大面积高密度牡蛎养殖有密切的关系。     

鸟粪对同里湿地公园土壤重金属及其形态的影响

为了解鸟粪对同里湿地公园土壤重金属全量及形态转化的影响,测定了公园内有鸟粪土壤、无鸟粪土壤、鸟粪沉积物的理化性质,Co、Cr、Cu、Ni、Zn全量及其形态分布,并进行统计分析。结果显示:同里湿地公园土壤及沉积物p H值平均含量达4.5,N、C、H、S和TP平均含量分别达到3.69、38.07、10.97、0.52、1.43g/kg,有鸟粪土壤中N、C、H和S含量显著高于无鸟粪土壤。Cu、Zn、Co平均含量呈现出鸟粪沉积物有鸟粪土壤无鸟粪土壤;Cr的平均含量表现为鸟粪沉积物无鸟粪土壤有鸟粪土壤;Ni呈现出有鸟粪土壤鸟粪沉积物无鸟粪土壤。总体上,鸟粪的进入增加了土壤Cu、Zn、Co、Ni含量。因此应及时清理土壤上覆鸟粪,降低对当地重金属污染风险。相对于无鸟粪土壤中不同重金属形态的分布,有鸟粪土壤中Co、Cr、Cu、Zn的活性态占全量的百分比均略有下降,非活性态呈上升趋势。鸟粪的加入,虽然会在一定程度上降低活性态重金属占总量的比例,但因总量和活性态含量均上升,向植物系统的迁移量会呈现增加趋势,因此对鸟粪施肥再利用应慎重。     

DDT降解菌株Chryseobacterium sp. PYR2对小麦的促生作用及其机理

【背景】前期结果表明,DDT降解菌株Chryseobacterium sp. PYR2可高效去除土壤中的DDT等污染物,具有潜在的应用价值,但该菌对植物的影响尚不清楚。【目的】探讨菌株Chryseobacterium sp. PYR2对植物的促生作用及其机理,为后续开发DDT降解及植物促生双效功能菌剂提供理论依据。【方法】配制该菌株的不同梯度稀释菌悬液,用纸卷发芽法和盆栽法研究菌悬液对小麦种子萌发和植株生长的影响;Salkowski法测定PYR2合成吲哚-3-乙酸(Indole-3-acetic acid,IAA)量;单因素实验研究不同培养条件对菌株生长及IAA合成的影响;液相色谱-串联质谱-多反应监测(LC-MS/MS-MRM)方法分析IAA在PYR2菌体内的生物合成途径。【结果】PYR2菌悬液可明显提高小麦种子萌发率并促进小麦植株的生长,小麦的侧根数、株高、鲜重、干重等指标均明显提高。该作用是由于菌株PYR2可以合成植物生长激素IAA。最适IAA合成条件:温度30°C,pH 7.0-8.0,盐浓度0.5%,L-色氨酸50mg/L。代谢液中检测到色醇、色胺和吲哚-3-乙酰胺3种中间代谢产物,推测PYR2体内存在3条IAA合成途径,分别为吲哚-3-丙酮酸(IPy A)、TAM和IAM途径。【结论】菌株PYR2对小麦具有明显的促生效果,是由于其具有多条高效合成IAA的代谢途径,表明其在农药污染土壤的生物修复及作物种植中具有潜在的应用前景。     

融合表达氨基转移酶DsaD和异构酶DsaE合成L-别异亮氨酸

【背景】L-异亮氨酸(L-isoleucine,L-Ile)和L-别异亮氨酸(L-allo-isoleucine,L-allo-Ile)是自然界中广泛存在的一对同分异构体。抗感染抗生素Desotamides结构中含L-别异亮氨酸结构单元,其生物合成途径中的氨基转移酶DsaD和异构酶DsaE可以协作催化L-异亮氨酸和L-别异亮氨酸相互转化。【目的】通过理性设计,使氨基转移酶DsaD和异构酶DsaE融合表达,研究融合蛋白DsaDE催化异亮氨酸和别异亮氨酸相互转化的功能。【方法】利用PCR分别扩增dsaE基因编码区DNA片段、以及含dsaD基因编码区和114个碱基接头序列的DNA片段dsaD-linker,利用酶切位点KpnI将dsaE和dsaD-linker相连,形成das DE重组序列,并克隆至pET28a(+)中,将重组质粒pET28a-dsaDE转化至Escherichia coli BL21(DE3)中进行融合表达,利用Ni-NTA亲和层析法纯化融合蛋白DsaDE;分别以L-异亮氨酸和L-别异亮氨酸为底物进行融合蛋白的体外酶活性检测,利用高效液相色谱对酶反应产物进行分析。【结果】PCR验证、酶切验证以及测序结果证明pET28a-dsaDE重组载体具有正确序列;N-末端和C-末端融合6个组氨酸标签的融合蛋白DsaDE在E. coli BL21(DE3)中获得可溶性表达,经Ni-NTA亲和层析法一步纯化获得纯度约95%的融合蛋白,纯化的融合蛋白DsaDE具有较好的活性,能够催化L-isoleucine和L-allo-isoleucine间的相互转化。【结论】氨基转移酶DsaD和异构酶DsaE成功融合表达,经一步Ni-NTA亲和层析法纯化即可获得纯度较高的融合蛋白,融合蛋白同时具有氨基转移酶和异构酶的活性,为进一步研究L-别异亮氨酸的工业化生产奠定了基础。     

柴油降解基因工程菌的构建及降解特性

【目的】构建柴油降解基因工程菌,提高柴油降解速率,研究p450基因在柴油降解过程中的作用。【方法】将Alcanivorax borkumensis SK2的p450基因合成后,连接至烷烃响应表达载体p Com8中,构建该基因的表达载体p450-SK2/p Com8,并将其转入大肠杆菌DH5α中,通过SDS-PAGE检测该基因在大肠杆菌DH5α中的表达,并将重组质粒p450-SK2/p Com8转入柴油降解菌Acinetobacter sp.Y9中,构建基因工程菌p450-SK2/Y9,研究工程菌p450-SK2/Y9对柴油的降解特性及p450基因在构建的工程菌p450-SK2/Y9中的表达。【结果】PCR、酶切及测序结果表明重组质粒p450-SK2/p Com8构建正确。当柴油诱导浓度大于1%时,目的基因在大肠杆菌DH5α中的蛋白表达量较大,且随着诱导时间的延长而呈增加趋势。通过PCR检测构建的基因工程菌p450-SK2/Y9中的p450基因表明,工程菌构建正确,利用单菌株降解柴油时,宿主菌Y9与工程菌p450-SK2/Y9的柴油降解效率未见明显差异,但工程菌p450-SK2/Y9在构建的菌群中对柴油降解的促进效果明显。SDS-PAGE结果表明,p450基因在构建的工程菌p450-SK2/Y9中能得到准确表达,在混合菌中的表达量高于单菌株。【结论】柴油降解基因工程菌在混合菌群中对柴油降解具有促进作用,而在单菌株情况下未见促进作用,且p450基因的蛋白表达在混合菌中也高于单菌株,这对于提高柴油的降解速率及研究p450基因在柴油降解过程中的作用机理具有一定意义。     

北京地区典型落叶阔叶乔木叶片含氮量和δ15N值对大气氮沉降的响应

为探究植物对大气氮沉降的响应和对这部分氮素的来源指示作用,本研究通过对北京地区198个采样点,典型落叶阔叶乔木杨属(Populus)和柳属(Salix)植物叶片进行采样,测定其叶片样品含氮量和δ~(15)N值。结果表明:北京地区杨属植物叶片含氮量为16.5—38.6g/kg,平均(24.0±4.0)g/kg;柳属植物叶片含氮量为17.2—36.2g/kg,平均(25.9±4.1)g/kg。研究区域范围内杨属、柳属植物叶片的含氮量均呈现出西北低、东南高的对角线型分布,与该区域大气氮沉降的空间变异相吻合。由于研究区域范围内气候因子无明显的变异,植物叶片的含氮量变化反应了大气氮沉降对植物元素化学计量特征的影响和植物对大气氮沉降的响应。北京地区杨属植物叶片δ~(15)N值为-3.95‰—8.10‰,平均(1.15±2.48)‰;柳属植物叶片δ~(15)N值为-3.04‰—9.73‰,平均(2.31±2.60)‰。杨属和柳属植物叶片的δ~(15)N值均呈现出西北高、中部高、东南低的空间分布,与叶片含氮量空间分布趋势相反。中部城区较高的δ~(15)N值反应了交通污染对大气含氮化合物增加的影响;西北部较高的δ~(15)N值反应了该区域受人为活动排放源的影响较少,自然的氮循环是其较高δ~(15)N值的主要原因;东南部较低的δ~(15)N值则有可能是由农业活动和交通共同作用的结果。     

Integration of a multicomponent intervention for hypertension into primary healthcare services in Singapore—A cluster randomized controlled trial

BackgroundDespite availability of clinical practice guidelines for hypertension management, blood pressure (BP) control remains sub-optimal (<30%) even in high-income countries. This study aims to assess the effectiveness of a potentially scalable multicomponent intervention integrated into primary care system compared to usual care on BP control.Methods and findingsA cluster-randomized controlled trial was conducted in 8 government clinics in Singapore. The trial enrolled 916 patients aged ≥40 years with uncontrolled hypertension (systolic BP (SBP) ≥140 mmHg or diastolic BP (DBP) ≥90 mmHg).Multicomponent intervention consisted of physician training in risk-based treatment of hypertension, subsidized losartan-HCTZ single-pill combination (SPC) medications, nurse training in motivational conversations (MCs), and telephone follow-ups. Usual care (controls) comprised of routine care in the clinics, no MC or telephone follow-ups, and no subsidy on SPCs. The primary outcome was mean SBP at 24 months’ post-baseline. Four clinics (447 patients) were randomized to intervention and 4 (469) to usual care. Patient enrolment commenced in January 2017, and follow-up was during December 2018 to September 2020. Analysis used intention-to-treat principles. The primary outcome was SBP at 24 months. BP at baseline, 12 and 24 months was modeled at the patient level in a likelihood-based, linear mixed model repeated measures analysis with treatment group, follow-up, treatment group × follow-up interaction as fixed effects, and random cluster (clinic) effects.A total of 766 (83.6%) patients completed 2-year follow-up. A total of 63 (14.1%) and 87 (18.6%) patients in intervention and in usual care, respectively, were lost to follow-up. At 24 months, the adjusted mean SBP was significantly lower in the intervention group compared to usual care (−3.3 mmHg; 95% CI: −6.34, −0.32; p = 0.03). The intervention led to higher BP control (odds ratio 1.51; 95% CI: 1.10, 2.09; p = 0.01), lower odds of high (>20%) 10-year cardiovascular risk score (OR 0.67; 95% CI: 0.47, 0.97; p = 0.03), and lower mean log albuminuria (−0.22; 95% CI: −0.41, −0.02; p = 0.03). Mean DBP, mortality rates, and serious adverse events including hospitalizations were not different between groups. The main limitation was no masking in the trial.ConclusionsA multicomponent intervention consisting of physicians trained in risk-based treatment, subsidized SPC medications, nurse-delivered motivational conversation, and telephone follow-ups improved BP control and lowered cardiovascular risk. Wide-scale implementation of a multicomponent intervention such as the one in our trial is likely to reduce hypertension-related morbidity and mortality globally.Trial registrationTrial Registration: Clinicaltrials.gov {"type":"clinical-trial","attrs":{"text":"NCT02972619","term_id":"NCT02972619"}}NCT02972619.

Tazeen H Jafar and colleagues present findings from a cluster-randomized controlled trial conducted to evaluate the effectiveness of an intervention designed to manage hypertension.     

Genome-wide CRISPR screen identifies synthetic lethality between DOCK1 inhibition and metformin in liver cancer

Metformin is currently a strong candidate anti-tumor agent in multiple cancers. However, its anti-tumor effectiveness varies among different cancers or subpopulations, potentially due to tumor heterogeneity. It thus remains unclear which hepatocellular carcinoma (HCC) patient subpopulation(s) can benefit from metformin treatment. Here, through a genome-wide CRISPR-Cas9-based knockout screen, we find that DOCK1 levels determine the anti-tumor effects of metformin and that DOCK1 is a synthetic lethal target of metformin in HCC. Mechanistically, metformin promotes DOCK1 phosphorylation, which activates RAC1 to facilitate cell survival, leading to metformin resistance. The DOCK1-selective inhibitor, TBOPP, potentiates anti-tumor activity by metformin in vitro in liver cancer cell lines and patient-derived HCC organoids, and in vivo in xenografted liver cancer cells and immunocompetent mouse liver cancer models. Notably, metformin improves overall survival of HCC patients with low DOCK1 levels but not among patients with high DOCK1 expression. This study shows that metformin effectiveness depends on DOCK1 levels and that combining metformin with DOCK1 inhibition may provide a promising personalized therapeutic strategy for metformin-resistant HCC patients.Supplementary InformationThe online version contains supplementary material available at 10.1007/s13238-022-00906-6.     

蜻蜓凤梨开花相关基因AfFPF1初步研究

FPF1 (flowering-promoting factor 1)是参与植物开花期遗传控制的重要家族之一。迄今为止,人们对蜻蜓凤梨中FPF1家族了解有限。本研究以热带花卉蜻蜓凤梨为材料,基于转录组测序数据,克隆获得AfFPF1基因。该基因编码的蛋白含103个氨基酸,分子质量为12.06 kD。AfFPF1转录本在蜻蜓凤梨的根中显著高表达,此外其表达量受外源乙烯强诱导,且响应赤霉素。AfFPF1基因在拟南芥中异位表达使其开花时间提前,莲座叶数目减少,促进其根系生长。对转基因拟南芥内源开花基因进行表达量检测,发现转基因植株中,一些开花促进基因如AtFT、AtAP1、AtLFY、AtFUL、AtSOC1表达量显著升高,而抑制开花基因AtFLC表达量下调,进一步证实AfFPF1能正调控拟南芥的开花时间,且可能与这些基因相互作用。研究结果初步证实AfFPF1可能参与调控蜻蜓凤梨开花过程,为进一步研究AfFPF1功能、通过基因工程调控蜻蜓凤梨开花以及乙烯诱导蜻蜓凤梨开花分子机制提供了理论依据。